Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16780344 | 0.73 | ALDH1A1 (0.36) | ALDH1A1POLBGAAKDM4ESMN1; SMN2 | |
| SCHEMBL1493391 | 0.69 | PIM1 (0.50) | PRMT5WDR77 | |
| SCHEMBL1493367 | 0.67 | LMNA (0.46) | ALDH1A1GAAKDM4ENPC1HSD17B10 | |
| SCHEMBL9970857 | 0.67 | PI4KA (0.40) | ALDH1A1POLBGAASMN1; SMN2GLA | |
| SCHEMBL3582094 | 0.65 | PI4KA (0.38) | ALDH1A1POLB | |
| SCHEMBL8228313 | 0.64 | DYRK1A (0.54) | ALDH1A1KDM4ENPC1MAPT | |
| SCHEMBL1857868 | 0.64 | NPC1 (0.54) | ALDH1A1GAAKDM4ENPC1HSD17B10 | |
| SCHEMBL17355073 | 0.64 | ALOX15 (0.58) | ALDH1A1GAAKDM4ENPC1HSD17B10 | |
| SCHEMBL8227604 | 0.63 | DYRK1A (0.41) | ALDH1A1POLBGAAKDM4ESMN1; SMN2 | |
| SCHEMBL4856665 | 0.63 | ALPL (0.58) | ALDH1A1GAAKDM4ENPC1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470539-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025951-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | ALDH1A1 1505/4885POLB 2053/4885GAA 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.